drugset
drugset / Trial / NCT05136404

A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

NCT05136404 ↗

Phase 1 Completed 42 enrolled Loxo Oncology, Inc. Eli Lilly and Company · collab
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as three different formulations in adult healthy participants. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 59 days including the 28 days of screening period.

Timeline

Start
2021-12-03
Primary completion
2022-03-14
Completion
2022-03-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Selpercatinib Small molecule 20 mg Oral
Subject Selpercatinib Small molecule 20 mg/ml Oral

Indications

No indication recorded.